Use of EP4 receptor antagonists in the treatment of cartilage disease
US10391086B2 · kind B2 · utility
2Cited by
1References
8Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Mar 5, 2018 |
| Grant date | Aug 27, 2019 |
| Priority date | — |
| Expiry date | Mar 5, 2038 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P19/02
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention is a method of treating osteoarthritis or normalizing a condition of osteoarthritis comprising administering to an animal or a human in need thereof a therapeutically effective amount of 3-[2-(4-{2-ethyl-4,6-dimethyl-1H-imidazo[4,5-c]pyridin-1-yl}phenyl)ethyl]-1-[(4-methylbenzene)sulfonyl]urea or a pharmaceutically acceptable salt thereof.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.